ASX Announcement

31 August 2020

Appointment of Rob Merriel to Board of Directors

Invion Limited (ASX.IVX) is pleased to announce the appointment of Rob Merriel as a Non-Executive Director with effect from 31 August 2020. Mr Merriel will stand for election at the 2020 Annual General Meeting to be held on 14 October 2020.

Mr Merriel brings deep healthcare sector experience and strong commercial expertise to the Board of Invion. He is a Certified Practicing Accountant (CPA) with over 35 years of experience working in medical research (Hudson Institute of Medical Research and Baker Institute), large public healthcare services (Melbourne Health and Southern Health) and commercial organisations (Pacific Dunlop and Deloitte Consulting).

He is currently on the Boards of two biotechnology start-up companies, he has been a Director of two Venture Capital Funds and a Director and Company Secretary of several biotechnology focused medical research institute spin-off companies.

Mr Merriel was appointed as the Chief Financial Officer, Chief Commercialisation Officer and Company Secretary of the Hudson Institute of Medical Research in May 2014, positions he continues to hold today. The Hudson is an independent, not-for-profit medical research institute, based in the Melbourne suburb of Clayton in Victoria, Australia. The Institute hosts approximately 450 researchers, postgraduate students and support staff.

Mr Merriel has been the Hudson Institute's lead in attracting three separate multi-million-dollar investments supporting the translation of discovery science into potential new therapies for patients. These investments were from Roche Pharmaceuticals, a Boston-based venture capital fund and an Australian venture capital fund. Mr Merriel also has detailed knowledge of the Australian government and philanthropic grant funding scheme landscape.

Melanie Farris has been a Director of Invion Ltd since December 2019. As announced to the ASX on 29 July 2020, Ms Farris retires as a director effective 31 August 2020 as part of a planned transition.

"I am very pleased to be able to announce a tremendous addition to the Board of Invion," commented Mr Thian Chew, Chairman of Invion Limited.

"Rob's addition to the Board broadens the depth of management and commercial experience at the Board table. I'd also like to take the opportunity to thank Melanie Farris for her outstanding contribution to the Company over the past several years and wish her success in her future endeavours."

Investor enquiries
Managing Director & CEO, Craig Newton
T: +61 3 9081 6005
E: investor@inviongroup.com

Media enquires
Brendon Lau
T: 0409 341 613
E: brendon@vantagepointpartners.com.au

About Invion

Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the PhotosoftTM technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.